Clinical trials: Multiple Sclerosis, Relapsing Remitting

Relapsing Remitting Multiple Sclerosis

Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).

• Completed
• Age: 18 to 55 years
• Phase 3
• Injection or infusion
• Results posted

Teva is developing a 40 mg/ml GA Injection, administered once daily under the skin, for the treatment of R-R MS. The study drug is a higher dose formulation of Copaxone® (20 mg/ml GA), a marketed medication, approved for the…

Trial name

NCT00337779

Testing

Glatiramer Acetate (GA) 40 mg, glatiramer acetate 20 mg

Volunteers

1,155 people

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.